SunTrust Banks Brokers Lift Earnings Estimates for Pfizer, Inc. (PFE)
Pfizer, Inc. (NYSE:PFE) – Equities research analysts at SunTrust Banks boosted their FY2017 EPS estimates for Pfizer in a report issued on Sunday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will post earnings of $2.56 per share for the year, up from their previous forecast of $2.54. SunTrust Banks also issued estimates for Pfizer’s Q4 2017 earnings at $0.59 EPS, FY2019 earnings at $2.78 EPS, FY2020 earnings at $2.77 EPS and FY2021 earnings at $2.84 EPS.
A number of other equities analysts also recently issued reports on PFE. Jefferies Group LLC reissued a “neutral” rating and issued a $35.00 price target (up from $34.00) on shares of Pfizer in a research note on Thursday, April 13th. Sanford C. Bernstein restated a “buy” rating and issued a $35.00 price objective on shares of Pfizer in a report on Monday, April 24th. BMO Capital Markets restated a “hold” rating and issued a $33.00 price objective on shares of Pfizer in a report on Thursday, April 27th. Barclays PLC restated a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a report on Wednesday, May 3rd. Finally, Citigroup Inc. cut shares of Pfizer from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $37.77.
ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/08/suntrust-banks-brokers-lift-earnings-estimates-for-pfizer-inc-pfe.html.
Pfizer (NYSE:PFE) opened at 33.31 on Tuesday. Pfizer has a 1-year low of $29.83 and a 1-year high of $35.53. The firm’s 50-day moving average price is $33.38 and its 200-day moving average price is $33.25. The firm has a market cap of $198.79 billion, a P/E ratio of 24.37 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the business posted $0.64 EPS.
A number of large investors have recently modified their holdings of the company. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer during the second quarter valued at about $102,000. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. boosted its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Finally, Herndon Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at about $120,000. Institutional investors own 70.10% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.84%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.